Comparison of efficacy and tolerability of adjuvant therapy for resected high-risk stage III-IV cutaneous melanoma: a systemic review and Bayesian network meta-analysis.
He BaFangyuan ZhuXiaoze ZhangZu-Bing MeiYaodong ZhuPublished in: Therapeutic advances in medical oncology (2023)
Considering efficacy and tolerability, nivolumab and pembrolizumab seem to be preferable adjuvant therapies for patients with stage III-IV melanoma. For BRAF mutation-positive patients, more RCTs are still required to determine which is better between ICIs and targeted therapy.
Keyphrases
- systematic review
- end stage renal disease
- prognostic factors
- open label
- ejection fraction
- newly diagnosed
- chronic kidney disease
- early stage
- peritoneal dialysis
- clinical trial
- lymph node
- double blind
- skin cancer
- meta analyses
- advanced non small cell lung cancer
- placebo controlled
- basal cell carcinoma
- epidermal growth factor receptor